These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

344 related items for PubMed ID: 7509000

  • 1. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy.
    Richman DD, Havlir D, Corbeil J, Looney D, Ignacio C, Spector SA, Sullivan J, Cheeseman S, Barringer K, Pauletti D.
    J Virol; 1994 Mar; 68(3):1660-6. PubMed ID: 7509000
    [Abstract] [Full Text] [Related]

  • 2. Natural occurrence of drug resistance mutations in the reverse transcriptase of human immunodeficiency virus type 1 isolates.
    Nájera I, Richman DD, Olivares I, Rojas JM, Peinado MA, Perucho M, Nájera R, López-Galíndez C.
    AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1479-88. PubMed ID: 7534096
    [Abstract] [Full Text] [Related]

  • 3. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.
    Tisdale M, Kemp SD, Parry NR, Larder BA.
    Proc Natl Acad Sci U S A; 1993 Jun 15; 90(12):5653-6. PubMed ID: 7685907
    [Abstract] [Full Text] [Related]

  • 4. Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2',3'-dideoxyinosine or AZT plus 2',3'-dideoxycytidine combination therapy. The protocol 34,225-02 Collaborative Group.
    Larder BA, Kohli A, Bloor S, Kemp SD, Harrigan PR, Schooley RT, Lange JM, Pennington KN, St Clair MH.
    J Virol; 1996 Sep 15; 70(9):5922-9. PubMed ID: 8709213
    [Abstract] [Full Text] [Related]

  • 5. Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy.
    Iversen AK, Shafer RW, Wehrly K, Winters MA, Mullins JI, Chesebro B, Merigan TC.
    J Virol; 1996 Feb 15; 70(2):1086-90. PubMed ID: 8551567
    [Abstract] [Full Text] [Related]

  • 6. Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy.
    Chow YK, Hirsch MS, Merrill DP, Bechtel LJ, Eron JJ, Kaplan JC, D'Aquila RT.
    Nature; 1993 Feb 18; 361(6413):650-4. PubMed ID: 7679778
    [Abstract] [Full Text] [Related]

  • 7. 3'-Azido-3'-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors.
    Larder BA.
    Antimicrob Agents Chemother; 1992 Dec 18; 36(12):2664-9. PubMed ID: 1282792
    [Abstract] [Full Text] [Related]

  • 8. Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro.
    Larder BA, Kellam P, Kemp SD.
    Nature; 1993 Sep 30; 365(6445):451-3. PubMed ID: 7692302
    [Abstract] [Full Text] [Related]

  • 9. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy.
    Larder BA, Kemp SD, Harrigan PR.
    Science; 1995 Aug 04; 269(5224):696-9. PubMed ID: 7542804
    [Abstract] [Full Text] [Related]

  • 10. Enzymatic properties of two mutants of reverse transcriptase of human immunodeficiency virus type 1 (tyrosine 181-->isoleucine and tyrosine 188-->leucine), resistant to nonnucleoside inhibitors.
    Loya S, Bakhanashvili M, Tal R, Hughes SH, Boyer PL, Hizi A.
    AIDS Res Hum Retroviruses; 1994 Aug 04; 10(8):939-46. PubMed ID: 7529032
    [Abstract] [Full Text] [Related]

  • 11. Combination therapy with zidovudine prevents selection of human immunodeficiency virus type 1 variants expressing high-level resistance to L-697,661, a nonnucleoside reverse transcriptase inhibitor.
    Staszewski S, Massari FE, Kober A, Göhler R, Durr S, Anderson KW, Schneider CL, Waterbury JA, Bakshi KK, Taylor VI.
    J Infect Dis; 1995 May 04; 171(5):1159-65. PubMed ID: 7538547
    [Abstract] [Full Text] [Related]

  • 12. Reverse transcriptase sequence of paired isolates of cerebrospinal fluid and blood from patients infected with human immunodeficiency virus type 1 during zidovudine treatment.
    Di Stefano M, Sabri F, Leitner T, Svennerholm B, Hagberg L, Norkrans G, Chiodi F.
    J Clin Microbiol; 1995 Feb 04; 33(2):352-5. PubMed ID: 7536214
    [Abstract] [Full Text] [Related]

  • 13. Transmission of human immunodeficiency virus type 1 resistant to nevirapine and zidovudine. Sydney Primary HIV Infection Study Group.
    Imrie A, Beveridge A, Genn W, Vizzard J, Cooper DA.
    J Infect Dis; 1997 Jun 04; 175(6):1502-6. PubMed ID: 9180194
    [Abstract] [Full Text] [Related]

  • 14. Alternating nevirapine and zidovudine treatment of human immunodeficiency virus type 1-infected persons does not prolong nevirapine activity.
    de Jong MD, Loewenthal M, Boucher CA, van der Ende I, Hall D, Schipper P, Imrie A, Weigel HM, Kauffmann RH, Koster R.
    J Infect Dis; 1994 Jun 04; 169(6):1346-50. PubMed ID: 8195615
    [Abstract] [Full Text] [Related]

  • 15. Mutational analysis of residue 190 of human immunodeficiency virus type 1 reverse transcriptase.
    Kleim JP, Bender R, Kirsch R, Meichsner C, Paessens A, Riess G.
    Virology; 1994 May 01; 200(2):696-701. PubMed ID: 7513921
    [Abstract] [Full Text] [Related]

  • 16. Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture.
    Richman D, Shih CK, Lowy I, Rose J, Prodanovich P, Goff S, Griffin J.
    Proc Natl Acad Sci U S A; 1991 Dec 15; 88(24):11241-5. PubMed ID: 1722324
    [Abstract] [Full Text] [Related]

  • 17. Treatment of human immunodeficiency virus type 1 (HIV-1)-infected cells with combinations of HIV-1-specific inhibitors results in a different resistance pattern than does treatment with single-drug therapy.
    Balzarini J, Karlsson A, Pérez-Pérez MJ, Camarasa MJ, Tarpley WG, De Clercq E.
    J Virol; 1993 Sep 15; 67(9):5353-9. PubMed ID: 7688822
    [Abstract] [Full Text] [Related]

  • 18. Resistance to 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives is generated by mutations at multiple sites in the HIV-1 reverse transcriptase.
    Buckheit RW, Fliakas-Boltz V, Yeagy-Bargo S, Weislow O, Mayers DL, Boyer PL, Hughes SH, Pan BC, Chu SH, Bader JP.
    Virology; 1995 Jun 20; 210(1):186-93. PubMed ID: 7540784
    [Abstract] [Full Text] [Related]

  • 19. Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. The AIDS Clinical Trials Group 143 Virology Team.
    Shafer RW, Iversen AK, Winters MA, Aguiniga E, Katzenstein DA, Merigan TC.
    J Infect Dis; 1995 Jul 20; 172(1):70-8. PubMed ID: 7541064
    [Abstract] [Full Text] [Related]

  • 20. Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility.
    Harrigan PR, Kinghorn I, Bloor S, Kemp SD, Nájera I, Kohli A, Larder BA.
    J Virol; 1996 Sep 20; 70(9):5930-4. PubMed ID: 8709214
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.